Splenic infarction

Cytovale Secures $84 Million Series C to Advance Commercialization of Transformative Sepsis Diagnostic Tool

Retrieved on: 
Wednesday, November 15, 2023
Septic, Attention, Sepsis, SAN, GHIC, Risk, ED, Patient, End organ damage, Probability, FDA, Partner, Norwest Venture Partners, MD, Infection, Death, Splenic infarction, Hospital, Mechanics, Face, Triage, Pharmaceutical industry, Nursing, Vaccine

SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced it has raised $84 million in Series C funding led by Norwest Venture Partners with participation by additional new investors Sands Capital and Global Health Investment Corporation (GHIC). The financing included participation from other new and existing investors, as well as the conversion of bridge notes. Cytovale will use the proceeds to bring its recently FDA-cleared rapid sepsis diagnosis test – IntelliSep® – to more hospital emergency departments (ED) and health systems in the United States, addressing historical diagnosis lag time that makes sepsis the leading cause of death in U.S. hospitals.

Key Points: 
  • "Sepsis is a dangerous, fast-moving condition that can result in death if not identified and treated quickly," said Cytovale CEO Ajay Shah.
  • "Our flagship diagnostic tool, IntelliSep, with a blood-to-answer time frame of under 10 minutes, helps healthcare providers recognize sepsis early and make critical, time-sensitive clinical decisions.
  • Sepsis is the leading cause of death in U.S. hospitals, with more than one-third of all in-hospital deaths attributed to the condition.
  • About 80% of sepsis patients present to the ED , where it can be difficult to discern from ordinary infections or other conditions that can mimic sepsis.

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI

Retrieved on: 
Monday, November 13, 2023
Medicine, Calcium, FAI, Chest pain, RCA, Plaque, American Heart Association, Risk, LAD, CCTA, CAD, Patient, Stenosis, Heart, MACE, Coronary artery disease, Blood, University, Late, Death, Cardiology, Splenic infarction, Biomarker, AI, Clinical, Medical imaging, Medical device, Pharmaceutical industry

PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ -- New research, presented today at the American Heart Association's Late Breaking Science Sessions, has found that AI technology from Caristo Diagnostics can predict fatal and non-fatal cardiac events independently from routine clinical risk scores and coronary computed tomography angiography (CCTA) interpretation, and can significantly impact treatment for coronary artery disease (CAD) by transforming risk stratification and management of patients undergoing routine CCTA.

Key Points: 
  • Clinical data from more than 40,000 patients were analyzed as part of the Oxford Risk Factors And Non-invasive imaging ( ORFAN ) study.
  • Among patients undergoing CCTA, the majority of fatal and non-fatal cardiac events occurred in those who did not have obstructive CAD at the time of imaging.
  • Specifically, there are twice as many heart attacks and cardiac deaths in the group without obstructive CAD versus those with obstructive CAD.
  • We look forward to introducing our technology across geographies to transform cardiac care and make heart attacks a preventable reality worldwide."

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI

Retrieved on: 
Monday, November 13, 2023
Medicine, Calcium, FAI, Chest pain, RCA, Plaque, American Heart Association, Risk, LAD, CCTA, CAD, Patient, Stenosis, Heart, MACE, Coronary artery disease, Blood, University, Late, Death, Cardiology, Splenic infarction, Biomarker, AI, Clinical, Medical imaging, Medical device, Pharmaceutical industry

PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ -- New research, presented today at the American Heart Association's Late Breaking Science Sessions, has found that AI technology from Caristo Diagnostics can predict fatal and non-fatal cardiac events independently from routine clinical risk scores and coronary computed tomography angiography (CCTA) interpretation, and can significantly impact treatment for coronary artery disease (CAD) by transforming risk stratification and management of patients undergoing routine CCTA.

Key Points: 
  • Clinical data from more than 40,000 patients were analyzed as part of the Oxford Risk Factors And Non-invasive imaging ( ORFAN ) study.
  • Among patients undergoing CCTA, the majority of fatal and non-fatal cardiac events occurred in those who did not have obstructive CAD at the time of imaging.
  • Specifically, there are twice as many heart attacks and cardiac deaths in the group without obstructive CAD versus those with obstructive CAD.
  • We look forward to introducing our technology across geographies to transform cardiac care and make heart attacks a preventable reality worldwide."

A High-Risk Antiphospholipid Antibody Profile Matters in Pediatric Patients with Antiphospholipid Syndrome

Retrieved on: 
Sunday, November 12, 2023
Medicine, Research, Artery, SAN, Immune system, Antiphospholipid syndrome, Weill Cornell Medicine, Woman, Risk, ACL, Hospital, Hospital for Special Surgery, Migraine, APS, Patient, APL, American College, American College of Rheumatology, Blood, Diagnosis, MPH, Arthritis, Antibody, Splenic infarction, Repository, ACR, Stroke, Vein, Classification, HSS, Nursing, Medical device, Rheumatology, MD

SAN DIEGO, Nov. 12, 2023 /PRNewswire/ -- A new study by Hospital for Special Surgery (HSS) investigators has found that an initial high-risk antibody profile for antiphospholipid syndrome (APS) tended to remain high in pediatric patients.

Key Points: 
  • SAN DIEGO, Nov. 12, 2023 /PRNewswire/ -- A new study by Hospital for Special Surgery (HSS) investigators has found that an initial high-risk antibody profile for antiphospholipid syndrome (APS) tended to remain high in pediatric patients.
  • "Our study reveals that an initial high-risk antiphospholipid antibody profile is unlikely to be transient in pediatric patients, indicating their risk of serious health problems remains elevated and they should be followed carefully."
  • For patients with symptoms, rheumatologists use three laboratory tests to evaluate the presence of aPL: lupus anticoagulant (LA), anticardiolipin antibody (aCL) and anti-beta-2-glycoprotein-1 antibody (aβ2GPI).
  • "An international effort has been initiated to pool pediatric APS data and ultimately guide the development of classification criteria for pediatric patients."

AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023

Retrieved on: 
Friday, November 10, 2023
Massachusetts General Hospital, Moyamoya disease, Research, Safety, Lipoprotein(a), Deficit spending, Consortium, Risk, AHA, Cholesterol, Hospital, Cardiovascular disease, Patient, Small RNA, OLE, LDL, Function (mathematics), MACE, American Heart Association, Stroke, Harvard Medical School, RNA, CVD, Splenic infarction, ASCVD, Dementia, Cardiology, Cone Health Women's Hospital, AMGN, Pharmaceutical industry, Evolocumab, Brigham, OCEAN, Amgen

THOUSAND OAKS, Calif., Nov. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia. These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C). Amgen will also present new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering RNA (siRNA) olpasiran that will focus on a primarily genetically determined and presumed independent CVD risk factor, lipoprotein(a) [Lp(a)].1,2,3,4,5

Key Points: 
  • These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C).
  • Amgen also shared new research from the OCEAN(a)-DOSE study on Lp(a) involving its investigational olpasiran.
  • Additional research presented at AHA will include Mass General Brigham Lp(a) registry data on whether the association between Lp(a) and major adverse cardiovascular events (MACE) differs based on baseline ASCVD status.
  • Amgen will reconvene the LDL-C Action Summit and the newly formed LDL Awareness to Action Implementation Consortium ahead of AHA.

City of Valencia Invests in IoT Project Powered by the Helium Network to Combat Energy Poverty

Retrieved on: 
Wednesday, November 8, 2023
Technology, IOT (Internet of Things), Philanthropy, Other Philanthropy, Other Technology, Telecommunications, Software, Networks, Internet, Foundation, Mobile, Wireless, Internet of things, Helium Network, Stroke, Splenic infarction, Weather, Health, Communication, Hypothermia, Multimedia, DSM-IV codes, Clima, City, Injury, Covenant, Risk, Partnership, LoRa, CO2, GHG, Redes, ICT, Movement, European, Information and communications technology, Energia, Renewable energy, Helium, Smart city

Health complications resulting from energy poverty include respiratory diseases, heart attacks, stroke, mental disorders, and acute health issues such as hypothermia, injury, or flu.

Key Points: 
  • Health complications resulting from energy poverty include respiratory diseases, heart attacks, stroke, mental disorders, and acute health issues such as hypothermia, injury, or flu.
  • Wellbased has distributed 130 sensors throughout the city of Valencia to address energy poverty.
  • Valencia advanced its mission by integrating the Helium Network, the world’s largest people-powered IoT Network.
  • Damal Redes, Helium, and the esteemed LoRa Alliance® collectively represent a step forward in addressing energy poverty.

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke

Retrieved on: 
Tuesday, November 7, 2023
Stroke, FDA, Standard of care, Trial of the century, AIS, MRS, Splenic infarction, Thrombectomy, Clinical trial, EMA, CET, Disability, Safety, Patient, Pharmaceutical industry

Gilles Avenard, General Manager of Acticor Biotech, declares: « We are pleased with the completion of the enrollment of our clinical study evaluating the efficacy of glenzocimab in 438 stroke patients exactly on schedule.

Key Points: 
  • Gilles Avenard, General Manager of Acticor Biotech, declares: « We are pleased with the completion of the enrollment of our clinical study evaluating the efficacy of glenzocimab in 438 stroke patients exactly on schedule.
  • We eagerly anticipate sharing the outcomes of this world-class study in the second quarter of 2024.
  • Deployed in the United States, Europe, Israel, and United Kingdom, ACTISAVE has enrolled 438 patients, of whom about 40% have undergone mechanical thrombectomy.
  • As previously announced, phase 2/3 clinical results are expected in the second quarter of 2024.

HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias

Retrieved on: 
Tuesday, November 7, 2023
Medical Devices, Health, Technology, Software, Cardiology, Biotechnology, Ischemia, Splenic infarction, ECG, Patent, Invention, AMI, AI, Diagnosis, Medical device

The latest patent, “Electrocardiogram Patch Devices and Methods” (Patent number 11,793,444) describes methods and systems for remote detection and/or diagnosis of acute myocardial infarction (AMI or heart attack) through handheld and adhesive devices.

Key Points: 
  • The latest patent, “Electrocardiogram Patch Devices and Methods” (Patent number 11,793,444) describes methods and systems for remote detection and/or diagnosis of acute myocardial infarction (AMI or heart attack) through handheld and adhesive devices.
  • An estimated 6 million ambulatory cardiac monitors are used annually in the US to assess intermittent heart symptoms.
  • One type of ambulatory cardiac monitor is an extended wear patch, generally consisting of a single lead ECG limiting detection of cardiac conditions, worn continually for up to 14 days.
  • “We believe our 12-lead ECG technology has the potential to become the standard of care and are actively pursuing options to bring the 12-lead extended wear patch to market.”

Family Medicine Specialists Selects Cardio Diagnostics’ Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients

Retrieved on: 
Tuesday, November 7, 2023
Technology, Biotechnology, Health, Biometrics, Other Health, Artificial Intelligence, Practice Management, Software, General Health, Genetics, Health Technology, Health Insurance, Data Management, Cardiology, Cardio, Splenic infarction, HMO, Obesity, Bangladesh Technical Education Board, Conditional sentence, Diabetes, Organization, Entrepreneurship, Milken Institute, Death, CDC, Risk, PPO, Hypertension, Blue Cross Blue Shield Association, Moyamoya disease, Patient, FMS, CHD, Cardiovascular disease, Heart failure, Medical device, Pharmaceutical industry, Medicaid

The "Heart Attack Prevention" initiative will leverage Cardio Diagnostics' advanced and highly sensitive blood-based epigenetic-genetic tests to risk stratify FMS’ patient population.

Key Points: 
  • The "Heart Attack Prevention" initiative will leverage Cardio Diagnostics' advanced and highly sensitive blood-based epigenetic-genetic tests to risk stratify FMS’ patient population.
  • According to the CDC, nearly 50% of Americans have at least one major cardiovascular risk such as diabetes, obesity, or hypertension.
  • FMS is implementing Cardio Diagnostics’ heart attack risk assessment test, Epi+Gen CHD, in at least 1,200 patients with CHD risk factors with BlueCross BlueShield Medicare, Medicaid, HMO and PPO health plans.
  • This initiative will demonstrate the practical and cost-effective benefits of early heart attack risk detection and intervention.

Avertix to Participate in the BTIG Digital Health Forum

Retrieved on: 
Monday, November 6, 2023
EVP, Splenic infarction, Patient, Pharmaceutical industry, Communications satellite

EATONTOWN, N.J. and NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, today announced that Tim Moran, President and Chief Executive Officer, and Philip Tom, EVP and Chief Financial Officer, are scheduled to attend the BTIG Digital Health Forum on November 20, 2023.

Key Points: 
  • EATONTOWN, N.J. and NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, today announced that Tim Moran, President and Chief Executive Officer, and Philip Tom, EVP and Chief Financial Officer, are scheduled to attend the BTIG Digital Health Forum on November 20, 2023.
  • Avertix management will engage in a fireside chat on Monday, November 20, 2023 at 3:30 p.m. Eastern Time.
  • Management will also engage in 1x1 meetings, which may be requested through BTIG.